The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Biogen Idec Inc  (BIIB) Trade Now »     Rate BIIB  -  Discuss BIIB  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
80.0%
Top:
66.5%
Rate BIIB:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

BIIB: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Who's Next in the Biotech Buyout Frenzy? Graphic_rating_buy BIIB
Mikerun
73%

Who's Next in the Biotech Buyout Frenzy?

<> The biotech industry is rapidly consolidating as big pharma companies put their cash stash to use in deals ranging from well-known large caps all the way down to unknown micro-caps in an effort to bolster their range of marketed products, late stage pipeline candidates, and drug discovery technology platforms.

Genentech (DNA) has rejected Roche's (RHHBY) $89 bid to acquire the remaining 44% of DNA it does not already own as insufficient. I think DNA could easily get $100 per share based on Eli Lilly's (LLY) $70 buyout of ImClo...
By  Mike Havrilla   (+1.04%  risk: conservative)  10/13/08 Comment


An Even Pfatter Yield at Pfizer Graphic_rating_buy BIIB
Mikerun
73%

An Even Pfatter Yield at Pfizer

<> As I have written previously on Pfizer (PFE), I continue to recommend shares of the Company as a turnaround play around the $15 per share level, which equates to an even fatter dividend yield of 8.5% since I first wrote about the stock in July trading two bucks higher before the market meltdown occurred. Despite significant patent challenges to Lipitor and other products in Pfizer’s portfolio over the next few years, the Company’s strong balance sheet, marketing muscle, and ability to bolster its pipeline through targeted acquisitions should < />< />< />< />< />< />...
By  Mike Havrilla   (+1.04%  risk: conservative)  10/12/08 Comment


Reiterating buy Graphic_rating_buy BIIB
Condor
41%
Got screwed by the Tysabri announcement but I believe this stock is going to climb back toward the drop point.  I target around $60 by the end of the year, if not higher.
By  Doodahdoodoo   (-5.62%  risk: aggressive)  09/15/08 Comment


Still bullish on this guy. Graphic_rating_buy BIIB
Condor
41%
Reiterating my BUY on this.  Too cheap.  Good company.
By  Doodahdoodoo   (-5.62%  risk: aggressive)  09/15/08 Comment


Clarity on Tysabri Makes Elan and Biogen a Buy Graphic_rating_buy BIIB
Rxlogo
50%

FDA Table of Potential Drug Risks - from Adverse Event Reporting System (AERS)

<> The FDA has published a table with the names of products and potential signals of serious risks and/or new safety information identified for these products during 1Q08 in the AERS database. The FDA notes that patients should not stop taking these medications and should consult their prescriber with any questions as the agency will investigate each of the claims further before taking action or issuing more definitive statements on the reported concerns. Some highlights from this table of produ...
By  Mike Havrilla   (-8.96%  risk: conservative)  09/06/08 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.25% 381
2 Gerald Greene 18.14 +72.34% 210
3 stockmarketfunding.com 17.66 +25.65% 55
4 akiralegrand 13.47 +14.32% 61
5 anup2104 12.13 +76.91% 39


POPULAR STOCKS
Symbol Company Name Sentiment
YHOO Yahoo! Inc
MSFT Microsoft Corp
RIO Companhia Vale Do Rio Doce
SBUX Starbucks Corp
GS Goldman Sachs Group Inc The
FNM Fannie Mae

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on BIIB

Visit streetinsider.com


Discussion Wall + Add  
amritadas   (+0.00%)
A FREE report on the approval of a new Gout Drug - FDA Panel to review this Biotech company's stress agent drug on July 28th. If they get a favorable backing by the panel, the chances of approval by th...
+   0 replies

amritadas   (+0.00%)
Free report on upcoming FDA panel decision of Corvu.. - FDA Panel to review this Biotech company's stress agent drug on July 28th. If they get a favorable backing by the panel, the chances of approval by th...
+   0 replies


More Resources

Graphic_arrow1 About Biogen Idec Inc - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch